A clinical trial monitored Erb-041 intake for its effects on rheumatoid arthritis over a 12-week period, and although treatment failed to show efficacy in patients, the study did report that Erb-041 was well-tolerated and exhibited a good safety profile [81]. Here, ESR2 is linked to rheumatoid arthritis.